mRNA-seq-based analysis predicts: AEG-1 is a therapeutic target and immunotherapy biomarker for pan-cancer, including OSCC
In conclusion, AEG-1 significantly correlates with prognosis and immune infiltration across various cancer types and holds potential as a novel prognostic immune biomarker for OSCC. This finding may facilitate the identification of patients who are most likely to benefit from adjuvant immunotherapy.
Authors
- Wanqiu Xu (ORCID: https://orcid.org/0000-0002-0464-1636)
- Guanghao Piao
- Lihong Yao (ORCID: https://orcid.org/0000-0002-3267-5980)
- Song Lin (ORCID: https://orcid.org/0000-0002-7423-7217)
- Hualei Xi
- Ying Liu (ORCID: https://orcid.org/0000-0002-6540-0473)
- Jinrong Guo
- Xiumei Wang (ORCID: https://orcid.org/0000-0002-1587-6406)
- Lixue Liu (ORCID: https://orcid.org/0009-0006-8630-6220)
Institutions
- Harbin Medical University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-17
- DOI
- https://doi.org/10.3389/fimmu.2024.1484226
- Citations
- 5
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.12